Apretude

The Food and Drug Administration approved Apretude for use as what’s known as pre-exposure prophylaxis, or PrEP, against HIV on Dec. 20. The long-acting drug, which is meant to be injected every two months by a health care worker, joined two daily pills — Gilead Sciences’ Truvada and Descovy — that were approved as PrEP […]

1. Cabotegravir was shown to be superior to TDF-FTC in preventing HIV infection in women. 2. Both drugs were well tolerated and had similar adverse effects; however, there was a greater incidence of injection site reactions in the cabotegravir group.

This Viewpoint discusses the recent FDA approval of cabotegravir, the first injectable medication to help prevent HIV infection, and how its effectiveness may be complicated by the cost and complexity of the US health care system.

More than 50 members of Congress have signed a letter to the Centers for Disease Control and Prevention and the Centers for Medicare and Medicaid Service asking the agencies to make a new injectable treatment for HIV prevention free for patients.

The FDA recently approved the use of an extended-release injectable formulation of the integrase inhibitor cabotegravir (CAB) for preexposure prophylaxis (PrEP) for adults and adolescents at risk for HIV infection. After two initial intramuscular (IM) injections given 1 month apart, it is administered every 2 months; it is the first non-oral PrEP therapy to become

Researchers used a widely published computer microsimulation model to examine the cost-effectiveness of long-acting injectable HIV PrEP compared to oral alternatives

Despite the high efficacy of pre-exposure prophylaxis (PrEP) in preventing HIV acquisition, PrEP uptake among Black cisgender women remains low. Our qualitative study assessed Black cisgender women’s perspectives, attitudes, and acceptability towards PrEP, in addition to exploring PrEP-related attitudes, facilitators, and barriers to PrEP access among health care staff.

Apretude (cabotegravir) is a long-acting injectable medication that can prevent HIV infection in people at risk for HIV exposure. Apretude is typically injected into the muscles of your buttocks every 2 months by a healthcare professional. Long-acting injectables can help improve medication adherence. And they are a great option if you don’t like daily pills.

“We have to focus on making sure that this product is really going to the health facilities and to the people who really must get it and can use it.”

AJMC commentary regarding the announcement of the U.S. Food and Drug Administration’s approval of Apretude